This trial is active, not recruiting.

Conditions allergic asthma, allergic rhinitis
Sponsor Creighton University
Collaborator Merck Sharp & Dohme Corp.
Start date May 2008
End date September 2011
Trial size 15 participants
Trial identifier NCT00710450, Townley Merck


Subjects with either allergic asthma or allergic rhinitis will be recruited to obtain blood. This blood will be used to be stimulated with to whatever the patient allergic. In the laboratory, this stimulated blood will be measured for histamine, leukotrienes, IL-13 and IL-3. These are chemicals responsible for allergy symptoms.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective
Allergic Asthma
Allergic Rhinitis

Primary Outcomes

Histamine Release
time frame: during the assay portion.

Secondary Outcomes

Cytokine release. IL-13, IL-4 and leukotriene
time frame: assay portion

Eligibility Criteria

Male or female participants at least 12 years old.

Inclusion Criteria: - Allergic asthma or allergic rhinitis - age 12+ Exclusion Criteria: - smokers

Additional Information

Official title The Effect of Montelukast In-vitro on Basophil Histamine and Leukotriene, IL-4 Adn IL-13 Release in Subjects With Allergic Rhinitis or Allergic Asthma
Trial information was received from ClinicalTrials.gov and was last updated in September 2011.
Information provided to ClinicalTrials.gov by Creighton University.